MagForce Nanotechnologies AG
frankfurt : MF6

October 10, 2011 03:17 ET

MagForce AG Announces Treatment of Recurrent Glioblastoma Patient with NanoTherm® Therapy

BERLIN--(Marketwire - Oct 10, 2011) -

. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

  * Patient treated at the University of Giessen and Charité
    University Medical Center Berlin in an interdisciplinary cooperation
  * The first treatment approvals have been received from German state
    insurance companies

MagForce AG (FSE: MF6), a leading medical technology company focusing on nanomedicine in oncology, announced today the treatment of a recurrent glioblastoma patient with the company's NanoTherm® therapy. The first part of the therapy (instillation of the nanoparticles) was carried out at the University Giessen and subsequent steps (nanoparticle activation and the accompanying radiotherapy) were performed at the Charité University Medical Center Berlin. Based on an individual patient agreement, the treatment costs are being covered by a German state insurance company.

"We are pleased that treatment with NanoTherm therapy for brain tumors patients has begun, and especially that treatment costs have been supported by a number of state insurance companies through individual patient agreements. This is a great milestone for both our novel technology and for MagForce as a company," said Dr. Peter Heinrich, CEO of MagForce. "Through our collaborations with experts in both Germany and internationally, we plan to further develop this treatment approach for a variety of solid tumor indications with high medical need."

Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Recurrent glioblastoma is the reoccurring growth following treatment of the primary tumor.


ABOUT MAGFORCE:

MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company's proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries.

ABOUT NANOTHERM® THERAPY

NanoTherm® therapy involves the direct injection of magnetic nanoparticles into the tumor and their subsequent heating by an alternating magnetic field. The water-soluble nanoparticles are approximately 15 nanometers in diameter and contain an iron oxide core with an aminosaline coating, which causes the particles to agglomerate following injection. The particles are then activated by a magnetic field that changes its polarity 100,000 times per second, and heat is produced within the tumor. Depending on the temperature reached and length of treatment, the tumor cells are either directly destroyed or sensitized for the accompanying chemotherapy or radiation.

DISCLAIMER:

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward- looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.


--- End of Message ---

MagForce Nanotechnologies AG

Max-Dohrn-Str. 8 Berlin Germany


Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MagForce Nanotechnologies AG via Thomson Reuters ONE

[HUG#1553355]

Contact Information

  • Contact:
    Stacy Wiedenmann
    Director Investor Relations & Corporate Communications
    MagForce AG
    Max-Dohrn-Str. 8
    10589 Berlin
    T +49 30 308 380 31
    F +49 30 308 380 99
    M +49 151 12000 722
    email:swiedenmann@magforce.com
    www.magforce.com